Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fosamac Reduces Multiple New Fracture Risk by up to 70% in Osteoporosis: Banyu Seminar
September 10, 2001
- Korosho Demands Budget of \18,745.5 Bil. for FY2002, Up 3.63%
September 10, 2001
- Combination of Thrombolytic, Cerebral Protective Agents Recommended for CI: MTP Seminar
September 10, 2001
- Korosho to Propose Healthcare System Reform at End of Sept.
September 10, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 10, 2001
- Goal Is 5 Years from Development to Approval: PMSB
September 10, 2001
- Latest Information Cannot Be Diffused Through Package Inserts: Seminar
September 10, 2001
- Bill for Revision of PAL to Be Submitted Next Diet Session
September 10, 2001
- BUSINESS NEWS IN BRIEF -2-
September 10, 2001
- To Bolster Globalization Based on Past Experiences: Mr Yoshino of Shionogi
September 10, 2001
- BUSINESS NEWS IN BRIEF -1-
September 10, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 10, 2001
- Additional Data Required for Sanwa Kagaku's SNK-860
September 10, 2001
- Kawasumi Potassium Adsorption Filter Recommended for Approval
September 10, 2001
- Toho Ties Up with Yakushin
September 10, 2001
- Banyu, Kyorin, Teijin to Start Immediate PMS for Montelukast, Alendronate
September 10, 2001
- Cerivastatin's Setback to Favor Sankyo's Mevalotin
September 10, 2001
- World News in Brief
September 3, 2001
- IPLS to Focus on Changing Licensing Business -2-
September 3, 2001
- IPLS to Focus on Changing Licensing Business -1-
September 3, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…